Reata Pharmaceuticals, Inc. (RETA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 172.32 |
| Open | 172.34 |
| Bid | 172.36 x 1100 |
| Ask | 172.40 x 1100 |
| Day's Range | 172.32 - 172.46 |
| 52 Week Range | 21.83 - 172.46 |
| Volume | |
| Avg. Volume | 954,093 |
| Market Cap | 6.566B |
| Beta (5Y Monthly) | 1.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 172.45 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RETA
Related Research
- Reata Pharmaceuticals, Inc.Daily – Vickers Top Buyers & Sellers for 06/15/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 months agoArgus Research
Insider MonkeyShould You Add Reata Pharmaceuticals (RETA) to Your Portfolio?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here. In the second quarter, the strategy underperformed the Russell 2000 Growth Index and returned 2.50% (net), and the index return was 7.05%. Consumer Staples, Health Care, Industrials, and Information […]
Business WireReata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
PLANO, Texas, September 21, 2023--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that at a special meeting held today, preliminary results indicate that the stockholders of the Company voted to approve the Company’s previously announced acquisition (the "Merger") by Biogen Inc., a Delaware corporation ("Biogen").
Simply Wall St.Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Is Expected To Breakeven In The Near Future
Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is possibly approaching a major achievement in its business, so we would...
